Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INZ 701

Next Previous
Drug Profile

INZ 701

Alternative Names: ENPP1-Fc; INZ-701; rhENPP1-Fc

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inozyme Pharma
  • Class Enzymes; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Calcinosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Calcinosis
  • Phase II Pseudoxanthoma elasticum
  • Phase I/II X-linked dominant hypophosphataemic rickets
  • Phase I Calciphylaxis
  • Research Unspecified

Most Recent Events

  • 16 May 2025 Inozyme Pharma anticipates regulatory approval in children in 2027
  • 14 May 2025 Inozyme Pharma announces intention to file regulatory application for approval of INZ 701 in Japan
  • 14 May 2025 Efficacy, adverse event and pharmacodynamics data from the phase III trial in Calcinosis released by Inozyme Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top